Xilio Therapeutics, a clinical-stage biopharmaceutical firm, is developing tumor-activated immunotherapies primarily targeting metastatic colorectal cancer. Over recent years, the company has progressively reduced operating losses while continuing negative cash flows, supported by capital raises including warrant exercises and pre-funded warrant offerings. Its future growth hinges on pivotal Phase 2 trials such as Vilastobart plus Atezolizumab, regulatory approvals, and sustained capital access. The firm's liquidity position was robust at the end of 2025, with over $137 million in cash and equivalents and a current ratio exceeding 2.5, ensuring runway into mid-2027.